{"id":26463,"date":"2012-04-16T03:57:07","date_gmt":"2012-04-16T07:57:07","guid":{"rendered":"http:\/\/asweetlife.org\/?p=26463"},"modified":"2015-12-30T03:26:45","modified_gmt":"2015-12-30T08:26:45","slug":"positive-results-for-biodels-ultra-rapid-acting-insulin","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=26463","title":{"rendered":"Positive Results for Biodel&#8217;s Ultra Rapid Acting Insulin"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Biodel-logo-1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-26465 lazyload\" title=\"Biodel logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Biodel-logo-1.png\" alt=\"\" width=\"204\" height=\"66\" \/><\/a>Biodel Inc.\u00a0announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 &#8212; two proprietary ultra rapid acting formulations of recombinant human insulin (RHI).\u00a0The objective of the trial was to identify an RHI-based formulation with pharmacokinetic and pharmacodynamic profiles similar to the company&#8217;s previous\u00a0ultra rapid acting\u00a0insulin\u00a0formulation,\u00a0Linjeta, \u00a0used in Phase 3 clinical trials, but with improved injection site toleration characteristics.\u00a0<\/p>\n<div style=\"text-align: justify;\">The Phase 1 clinical trial was a single-center, randomized, double-blind, three-period crossover trial in 12 patients with type 1 diabetes.\u00a0 Each study drug was administered subcutaneously on separate days with a washout period between injections.\u00a0<\/div>\n<div>\n<p style=\"text-align: justify;\">In the phase 1 clinical trial, absorption rates of Biodel&#8217;s\u00a0ultra rapid acting\u00a0insulin&#8217;s BIOD-123 and BIOD-125 were significantly faster than that of Humalog as indicated by 64% and 54% reductions, respectively.\u00a0 In a previous clinical trial, the Linjeta formulation demonstrated a 61% reduction compared to Humalog.\u00a0 Peak metabolic effects were not significantly different between the three study drugs.\u00a0<\/p>\n<p style=\"text-align: justify;\">All three drugs were well tolerated, with injection site tolerability generally perceived by patients to be similar to that of their usual mealtime injections used at home.\u00a0 As measured on a 100 mm visual analog scale in which 100 mm is defined as the worst possible injection discomfort, local toleration was not significantly different for BIOD-123 compared to Humalog.\u00a0 The VAS score for BIOD-125 was slightly higher as compared to Humalog.\u00a0 However, this score was markedly improved relative to the Linjeta formulation.<\/p>\n<div style=\"text-align: justify;\">The\u00a0encouraging\u00a0findings from these studies \u00a0will enable Biodel to advance the ultra rapid acting insulin into a Phase 2 clinical trial as early as next quarter.\u00a0 In parallel, the company will continue its development of ultra rapid acting insulin analog-based formulations, with the goal of advancing product candidates into a Phase 1 clinical trial later in 2012. \u00a0<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biodel Inc. announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 &#8212; two proprietary ultra rapid acting formulations of recombinant human insulin (RHI). The objective of the trial was to identify&#8230;<\/p>\n","protected":false},"author":131,"featured_media":27870,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[488,862],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Positive Results for Biodel&#039;s Ultra Rapid Acting Insulin<\/title>\n<meta name=\"description\" content=\"In the phase 1 clinical trial absorption rates of Biodel&#039;s ultra rapid acting insulin&#039;s were significantly faster than that of Humalog...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=26463\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=26463\",\"url\":\"https:\/\/asweetlife.org\/?p=26463\",\"name\":\"Positive Results for Biodel's Ultra Rapid Acting Insulin\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26463#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26463#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png\",\"datePublished\":\"2012-04-16T07:57:07+00:00\",\"dateModified\":\"2015-12-30T08:26:45+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"In the phase 1 clinical trial absorption rates of Biodel's ultra rapid acting insulin's were significantly faster than that of Humalog...\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26463#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=26463\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=26463#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png\",\"width\":175,\"height\":75,\"caption\":\"biodel_logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=26463#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positive Results for Biodel&#8217;s Ultra Rapid Acting Insulin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Positive Results for Biodel's Ultra Rapid Acting Insulin","description":"In the phase 1 clinical trial absorption rates of Biodel's ultra rapid acting insulin's were significantly faster than that of Humalog...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=26463","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=26463","url":"https:\/\/asweetlife.org\/?p=26463","name":"Positive Results for Biodel's Ultra Rapid Acting Insulin","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=26463#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=26463#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png","datePublished":"2012-04-16T07:57:07+00:00","dateModified":"2015-12-30T08:26:45+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"In the phase 1 clinical trial absorption rates of Biodel's ultra rapid acting insulin's were significantly faster than that of Humalog...","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=26463#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=26463"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=26463#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/06\/biodel_logo.png","width":175,"height":75,"caption":"biodel_logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=26463#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Positive Results for Biodel&#8217;s Ultra Rapid Acting Insulin"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/26463"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26463"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/26463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/27870"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}